JP2018500012A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018500012A5 JP2018500012A5 JP2017526681A JP2017526681A JP2018500012A5 JP 2018500012 A5 JP2018500012 A5 JP 2018500012A5 JP 2017526681 A JP2017526681 A JP 2017526681A JP 2017526681 A JP2017526681 A JP 2017526681A JP 2018500012 A5 JP2018500012 A5 JP 2018500012A5
- Authority
- JP
- Japan
- Prior art keywords
- rodent
- gene
- human
- polypeptide
- humanized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462087992P | 2014-12-05 | 2014-12-05 | |
| US62/087,992 | 2014-12-05 | ||
| PCT/US2015/062614 WO2016089692A1 (en) | 2014-12-05 | 2015-11-25 | Non-human animals having a humanized cluster of differentiation 47 gene |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020114628A Division JP7089554B2 (ja) | 2014-12-05 | 2020-07-02 | ヒト化されたcluster of differentiation 47遺伝子を有する非ヒト動物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018500012A JP2018500012A (ja) | 2018-01-11 |
| JP2018500012A5 true JP2018500012A5 (enExample) | 2018-12-13 |
| JP6730277B2 JP6730277B2 (ja) | 2020-07-29 |
Family
ID=54979926
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017526681A Active JP6730277B2 (ja) | 2014-12-05 | 2015-11-25 | ヒト化されたcluster of differentiation 47遺伝子を有する非ヒト動物 |
| JP2020114628A Active JP7089554B2 (ja) | 2014-12-05 | 2020-07-02 | ヒト化されたcluster of differentiation 47遺伝子を有する非ヒト動物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020114628A Active JP7089554B2 (ja) | 2014-12-05 | 2020-07-02 | ヒト化されたcluster of differentiation 47遺伝子を有する非ヒト動物 |
Country Status (29)
| Country | Link |
|---|---|
| US (5) | US20160345549A1 (enExample) |
| EP (4) | EP4296278A3 (enExample) |
| JP (2) | JP6730277B2 (enExample) |
| KR (3) | KR102313073B1 (enExample) |
| CN (2) | CN107205368B (enExample) |
| AR (1) | AR102888A1 (enExample) |
| AU (2) | AU2015355328B2 (enExample) |
| BR (1) | BR112017010490A2 (enExample) |
| CA (1) | CA2967834C (enExample) |
| CY (2) | CY1121547T1 (enExample) |
| DK (3) | DK3086637T3 (enExample) |
| ES (3) | ES2969389T3 (enExample) |
| FI (1) | FI3850946T3 (enExample) |
| HR (3) | HRP20190634T1 (enExample) |
| HU (3) | HUE043132T2 (enExample) |
| IL (2) | IL286403B2 (enExample) |
| LT (3) | LT3466255T (enExample) |
| MX (1) | MX2017007293A (enExample) |
| NZ (2) | NZ769992A (enExample) |
| PL (3) | PL3850946T3 (enExample) |
| PT (3) | PT3850946T (enExample) |
| RS (3) | RS58536B1 (enExample) |
| RU (1) | RU2728412C2 (enExample) |
| SG (2) | SG10202103050YA (enExample) |
| SI (3) | SI3086637T1 (enExample) |
| SM (3) | SMT201900178T1 (enExample) |
| TR (1) | TR201903891T4 (enExample) |
| TW (1) | TWI681053B (enExample) |
| WO (1) | WO2016089692A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107205368B (zh) | 2014-12-05 | 2020-11-17 | 瑞泽恩制药公司 | 具有人源化分化簇47基因的非人动物 |
| SMT202400313T1 (it) | 2014-12-09 | 2024-09-16 | Regeneron Pharma | Animali non umani aventi un cluster umanizzato di un gene di differenziazione 274 |
| WO2016154299A1 (en) * | 2015-03-24 | 2016-09-29 | The Trustees Of Columbia University In The City Of New York | Genetic modification of pigs for xenotransplantation |
| BR112017025507A2 (pt) | 2015-05-29 | 2018-08-07 | Regeneron Pharmaceuticals, Inc. | roedor, célula isolada de roedor ou tecido isolado de roedor, célula-tronco embrionária de roedor, embrião de roedor, e, métodos para preparação de um roedor e para identificação de um candidato terapêutico. |
| RS61866B1 (sr) | 2015-11-20 | 2021-06-30 | Regeneron Pharma | Ne-humane životinje koje imaju humanizovani gen za aktivaciju limfocita 3 |
| JP6843872B2 (ja) | 2016-02-04 | 2021-03-17 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 操作されたangptl8遺伝子を有する非ヒト動物 |
| RU2749715C2 (ru) | 2016-02-29 | 2021-06-16 | Регенерон Фармасьютикалз, Инк. | Грызуны, характеризующиеся гуманизированным геном tmprss |
| SG10202101133SA (en) * | 2016-08-11 | 2021-03-30 | Jackson Lab | Methods and compositions relating to improved human red blood cell survival in genetically modified immunodeficient non-human animals |
| CN107815465B (zh) | 2016-08-31 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化基因改造动物模型的制备方法及应用 |
| WO2018041121A1 (en) | 2016-08-31 | 2018-03-08 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric ctla-4 |
| CN107815468B (zh) * | 2016-08-31 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化基因改造动物模型的制备方法及应用 |
| WO2018041119A1 (en) | 2016-08-31 | 2018-03-08 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric ox40 |
| WO2018064600A1 (en) * | 2016-09-30 | 2018-04-05 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a hexanucleotide repeat expansion in a c9orf72 locus |
| CN108467873B (zh) | 2017-03-17 | 2020-03-13 | 百奥赛图江苏基因生物技术有限公司 | 一种cd132基因缺失的免疫缺陷动物模型的制备方法及应用 |
| WO2018177441A1 (en) | 2017-03-31 | 2018-10-04 | Beijing Biocytogen Co., Ltd | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPα |
| CN108588126B (zh) * | 2017-03-31 | 2020-04-10 | 北京百奥赛图基因生物技术有限公司 | Cd47基因人源化改造动物模型的制备方法及应用 |
| IL270835B2 (en) * | 2017-06-12 | 2025-01-01 | Sinai Health Sys | Allograft tolerance without the need for systemic immunosuppression |
| US11401329B2 (en) | 2017-08-02 | 2022-08-02 | Phanes Therapeutics, Inc. | Anti-CD47 antibodies and uses thereof |
| CN111655031B (zh) * | 2017-11-30 | 2022-11-18 | 瑞泽恩制药公司 | 包含人源化trkb基因座的非人动物 |
| WO2019190990A1 (en) | 2018-03-26 | 2019-10-03 | Regeneron Pharmaceuticals, Inc. | Humanized rodents for testing therapeutic agents |
| PT3823443T (pt) | 2018-07-16 | 2024-07-29 | Regeneron Pharma | Modelos de roedores da-doença ditra e as suas utilizações |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| IL301193A (en) | 2018-12-20 | 2023-05-01 | Regeneron Pharma | Nuclease-mediated repeat expansion |
| CN111218425B (zh) * | 2019-01-17 | 2022-02-08 | 百奥赛图(北京)医药科技股份有限公司 | 人源化转基因动物 |
| WO2021027737A1 (en) * | 2019-08-09 | 2021-02-18 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric il2ra |
| WO2021043290A1 (en) * | 2019-09-06 | 2021-03-11 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd | Genetically modified non-human animal with human or chimeric tnfr2 |
| WO2021136537A1 (en) * | 2019-12-31 | 2021-07-08 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | GENETICALLY MODIFIED IMMUNODEFICIENT NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPα/CD47 |
| CN112080522A (zh) * | 2020-09-15 | 2020-12-15 | 广东药康生物科技有限公司 | 一种cd47人源化小鼠模型的构建方法 |
| CN112725379B (zh) * | 2021-01-27 | 2024-08-13 | 上海南方模式生物科技股份有限公司 | 人源化cd40基因改造动物模型的构建方法及应用 |
| CN116064558A (zh) * | 2021-09-24 | 2023-05-05 | 百奥赛图(北京)医药科技股份有限公司 | Trop2基因人源化非人动物的构建方法及应用 |
| WO2024020057A1 (en) | 2022-07-19 | 2024-01-25 | Regeneron Pharmaceuticals, Inc. | Genetically modified animal model and its use to model the human immune system |
| WO2025171307A1 (en) | 2024-02-08 | 2025-08-14 | Regeneron Pharmaceuticals, Inc. | Vectors, genetically modified cells, and genetically modified non-human animals comprising the same |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5670356A (en) | 1994-12-12 | 1997-09-23 | Promega Corporation | Modified luciferase |
| US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| AU2004287722A1 (en) * | 2003-11-11 | 2005-05-19 | Chugai Seiyaku Kabushiki Kaisha | Humanized anti-CD47 antibody |
| PT1802193E (pt) | 2004-10-19 | 2014-06-23 | Regeneron Pharma | Método para gerar um murganho homozigótico para uma modificação genética |
| US20070113297A1 (en) * | 2005-09-13 | 2007-05-17 | Yongguang Yang | Methods and compositions for inhibition of immune responses |
| EP2064325B1 (en) * | 2006-09-01 | 2011-12-07 | Therapeutic Human Polyclonals, Inc. | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals |
| WO2009039244A2 (en) * | 2007-09-18 | 2009-03-26 | Genizon Biosciences Inc. | Genemap of the human genes associated with crohn's disease |
| CN101668387A (zh) | 2008-09-02 | 2010-03-10 | 鸿富锦精密工业(深圳)有限公司 | 印刷电路板 |
| CN102281758B (zh) * | 2009-01-16 | 2014-12-10 | 公益财团法人实验动物中央研究所 | 移植了人肝细胞的小鼠 |
| RU2425880C2 (ru) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
| WO2011020014A1 (en) | 2009-08-14 | 2011-02-17 | Regeneron Pharmaceuticals, Inc. | Promoter-regulated differentiation-dependent self-deleting cassette |
| SI2477648T1 (sl) * | 2009-09-15 | 2022-09-30 | The Board Of Trustees Of The Leland Stanford Junior University | Sinergijska terapija proti CD47 za krvne rake |
| EP4049535B1 (en) | 2009-10-06 | 2024-11-27 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice and engraftment |
| RU2730643C2 (ru) | 2011-02-15 | 2020-08-24 | Ридженерон Фармасьютикалз, Инк. | Гуманизированные m-csf мыши |
| WO2013056352A1 (en) * | 2011-10-19 | 2013-04-25 | University Health Network | Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers |
| SG10201909638UA (en) | 2011-10-28 | 2019-11-28 | Regeneron Pharma | Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules |
| DK3262932T3 (da) | 2011-10-28 | 2019-08-05 | Regeneron Pharma | Genmodificerede mus med major histokompatibilitetskompleks |
| ES2624605T3 (es) | 2011-10-28 | 2017-07-17 | Regeneron Pharmaceuticals, Inc. | IL-6 y receptor de IL-6 humanizados |
| EP2644027A1 (en) * | 2012-03-26 | 2013-10-02 | Institut Pasteur | Transgenic immunodefficient mouse expressing human SIRPalpha. |
| US8962913B2 (en) | 2012-06-18 | 2015-02-24 | Regeneron Pharmaceuticals, Inc. | Humanized IL-7 rodents |
| JP6283031B2 (ja) | 2012-09-07 | 2018-02-21 | イエール ユニバーシティ | 遺伝学的に修飾された非ヒト動物およびその使用法 |
| EP3308641B1 (en) * | 2012-11-05 | 2019-07-03 | Regeneron Pharmaceuticals, Inc. | Immunodeficient, genetically modified rodent and methods of use thereof |
| CN105102479B (zh) * | 2012-12-12 | 2019-06-28 | 瓦斯库劳克斯有限公司 | 治疗性cd47抗体 |
| CN111484999B (zh) | 2013-02-20 | 2024-10-25 | 瑞泽恩制药公司 | 人源化的t细胞共受体的小鼠 |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| US10154658B2 (en) | 2013-02-22 | 2018-12-18 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| SMT201900067T1 (it) | 2013-09-23 | 2019-02-28 | Regeneron Pharma | Animali non umani aventi un gene di proteina regolatoria del segnale umanizzato |
| HRP20170380T1 (hr) | 2013-10-15 | 2017-05-19 | Regeneron Pharmaceuticals, Inc. | Životinje s humaniziranim il-5 |
| CA2929774C (en) | 2013-11-19 | 2020-09-15 | Regeneron Pharmaceuticals, Inc. | Non-human animal cells having a humanized proliferation-inducing ligand gene |
| ES2700972T3 (es) | 2013-11-19 | 2019-02-20 | Regeneron Pharma | Animales no humanos que tienen un gen de factor activador de células B humanizado |
| SG10201908800YA (en) | 2014-04-08 | 2019-11-28 | Regeneron Pharma | Non-human animals having humanized fc-gamma receptors |
| NO2785538T3 (enExample) | 2014-05-07 | 2018-08-04 | ||
| CA2947309A1 (en) | 2014-05-19 | 2015-11-26 | Regeneron Pharmaceuticals, Inc. | Genetically modified non-human animals expressing human epo |
| RS60097B1 (sr) | 2014-06-19 | 2020-05-29 | Regeneron Pharma | Ne-humane životinje koje imaju humanizovani gen za programiranu ćelijsku smrt 1 |
| RU2020122439A (ru) | 2014-11-24 | 2020-09-24 | Регенерон Фармасьютикалз, Инк. | Не относящиеся к человеку животные, экспрессирующие гуманизированный комплекс cd3 |
| CN107205368B (zh) | 2014-12-05 | 2020-11-17 | 瑞泽恩制药公司 | 具有人源化分化簇47基因的非人动物 |
-
2015
- 2015-11-25 CN CN201580066047.0A patent/CN107205368B/zh active Active
- 2015-11-25 LT LTEP18207075.5T patent/LT3466255T/lt unknown
- 2015-11-25 HU HUE15813960A patent/HUE043132T2/hu unknown
- 2015-11-25 LT LTEP15813960.0T patent/LT3086637T/lt unknown
- 2015-11-25 ES ES20215046T patent/ES2969389T3/es active Active
- 2015-11-25 HR HRP20190634TT patent/HRP20190634T1/hr unknown
- 2015-11-25 PT PT202150462T patent/PT3850946T/pt unknown
- 2015-11-25 HU HUE20215046A patent/HUE064960T2/hu unknown
- 2015-11-25 MX MX2017007293A patent/MX2017007293A/es unknown
- 2015-11-25 SM SM20190178T patent/SMT201900178T1/it unknown
- 2015-11-25 RS RS20190370A patent/RS58536B1/sr unknown
- 2015-11-25 NZ NZ769992A patent/NZ769992A/en unknown
- 2015-11-25 DK DK15813960.0T patent/DK3086637T3/en active
- 2015-11-25 WO PCT/US2015/062614 patent/WO2016089692A1/en not_active Ceased
- 2015-11-25 PL PL20215046.2T patent/PL3850946T3/pl unknown
- 2015-11-25 KR KR1020177013948A patent/KR102313073B1/ko active Active
- 2015-11-25 SM SM20210281T patent/SMT202100281T1/it unknown
- 2015-11-25 US US14/951,825 patent/US20160345549A1/en not_active Abandoned
- 2015-11-25 ES ES18207075T patent/ES2870462T3/es active Active
- 2015-11-25 PT PT182070755T patent/PT3466255T/pt unknown
- 2015-11-25 SI SI201530659T patent/SI3086637T1/sl unknown
- 2015-11-25 HU HUE18207075A patent/HUE054661T2/hu unknown
- 2015-11-25 NZ NZ731471A patent/NZ731471A/en unknown
- 2015-11-25 TR TR2019/03891T patent/TR201903891T4/tr unknown
- 2015-11-25 KR KR1020237007814A patent/KR102617691B1/ko active Active
- 2015-11-25 SI SI201531599T patent/SI3466255T1/sl unknown
- 2015-11-25 RU RU2017123357A patent/RU2728412C2/ru active
- 2015-11-25 PT PT15813960T patent/PT3086637T/pt unknown
- 2015-11-25 CA CA2967834A patent/CA2967834C/en active Active
- 2015-11-25 DK DK20215046.2T patent/DK3850946T5/da active
- 2015-11-25 CN CN202011160730.XA patent/CN112342197B/zh active Active
- 2015-11-25 JP JP2017526681A patent/JP6730277B2/ja active Active
- 2015-11-25 ES ES15813960T patent/ES2716735T3/es active Active
- 2015-11-25 SM SM20230482T patent/SMT202300482T1/it unknown
- 2015-11-25 EP EP23192469.7A patent/EP4296278A3/en active Pending
- 2015-11-25 HR HRP20231707TT patent/HRP20231707T1/hr unknown
- 2015-11-25 SG SG10202103050YA patent/SG10202103050YA/en unknown
- 2015-11-25 PL PL15813960T patent/PL3086637T3/pl unknown
- 2015-11-25 RS RS20231251A patent/RS64989B1/sr unknown
- 2015-11-25 PL PL18207075T patent/PL3466255T3/pl unknown
- 2015-11-25 FI FIEP20215046.2T patent/FI3850946T3/fi active
- 2015-11-25 SI SI201531982T patent/SI3850946T1/sl unknown
- 2015-11-25 IL IL286403A patent/IL286403B2/en unknown
- 2015-11-25 KR KR1020217032415A patent/KR102508175B1/ko active Active
- 2015-11-25 EP EP18207075.5A patent/EP3466255B1/en active Active
- 2015-11-25 AU AU2015355328A patent/AU2015355328B2/en active Active
- 2015-11-25 EP EP20215046.2A patent/EP3850946B1/en active Active
- 2015-11-25 SG SG11201703463WA patent/SG11201703463WA/en unknown
- 2015-11-25 DK DK18207075.5T patent/DK3466255T3/da active
- 2015-11-25 LT LTEP20215046.2T patent/LT3850946T/lt unknown
- 2015-11-25 RS RS20210547A patent/RS61774B1/sr unknown
- 2015-11-25 BR BR112017010490A patent/BR112017010490A2/pt not_active Application Discontinuation
- 2015-11-25 EP EP15813960.0A patent/EP3086637B1/en active Active
- 2015-12-03 AR ARP150103952A patent/AR102888A1/es unknown
- 2015-12-03 TW TW104140456A patent/TWI681053B/zh active
-
2016
- 2016-01-19 US US15/000,751 patent/US10015953B2/en active Active
-
2017
- 2017-04-30 IL IL252019A patent/IL252019B/en unknown
-
2018
- 2018-05-17 US US15/982,174 patent/US10939673B2/en active Active
-
2019
- 2019-03-21 CY CY20191100334T patent/CY1121547T1/el unknown
-
2020
- 2020-07-02 JP JP2020114628A patent/JP7089554B2/ja active Active
-
2021
- 2021-01-29 US US17/161,801 patent/US11910788B2/en active Active
- 2021-04-27 HR HRP20210662TT patent/HRP20210662T1/hr unknown
- 2021-05-06 CY CY20211100382T patent/CY1124089T1/el unknown
-
2022
- 2022-06-02 AU AU2022203787A patent/AU2022203787B2/en active Active
-
2024
- 2024-01-16 US US18/413,219 patent/US12389889B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018500012A5 (enExample) | ||
| JP7649370B2 (ja) | 抗kras-g12d t細胞受容体 | |
| Ma et al. | Monocyte-derived macrophages promote breast cancer bone metastasis outgrowth | |
| JP7168641B2 (ja) | 刺激性骨髄系細胞及び非刺激性骨髄系細胞の調節 | |
| JP6945444B2 (ja) | 高親和性pd−1薬剤とその使用方法 | |
| AU2017355218B2 (en) | Immunologically discernible cell surface variants for use in cell therapy | |
| JP6665269B2 (ja) | ヒト化シグナル調節タンパク質遺伝子を有する非ヒト動物 | |
| Antonioli et al. | Anti-CD73 in cancer immunotherapy: awakening new opportunities | |
| JP2019047818A5 (enExample) | ||
| EP3209769B1 (en) | Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance | |
| JP7611836B2 (ja) | 抗原特異的t細胞の同定のための組成物と方法 | |
| US12187801B2 (en) | Chimeric antigen receptors against AXL or ROR2 and methods of use thereof | |
| JP2021166522A (ja) | キメラ抗原受容体組成物 | |
| RU2017123357A (ru) | Животные, отличные от человека, имеющие гуманизированный ген кластера дифференцировки 47 | |
| JP2019536480A (ja) | T細胞悪性腫瘍の免疫療法のためのcd7発現およびキメラ抗原受容体の遮断 | |
| CN112867503A (zh) | 掩蔽的细胞因子缀合物 | |
| US20170267755A1 (en) | Isolated anti-mesothelin antibodies, conjugates and uses thereof | |
| JP2016514099A5 (enExample) | ||
| CN109152837A (zh) | 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法 | |
| US20210213055A1 (en) | Compositions and methods for inducing phagocytosis | |
| KR20190027832A (ko) | 향상된 효능을 갖는 치료를 위한 질병-특이적 표적으로서 네오에피토프의 선택 | |
| Chao et al. | Effector T cell responses unleashed by regulatory T cell ablation exacerbate oral squamous cell carcinoma | |
| CN111629715A (zh) | 通过调节细胞活化状态改变体内免疫细胞的炎症状态 | |
| Bandara et al. | Pre-clinical validation of a pan-cancer CAR-T cell immunotherapy targeting nfP2X7 | |
| EP3678673A1 (en) | Compositions and processes for targeted delivery, expression and modulation of coding ribonucleic acids in tissue |